Schering Profit Falls; Forecast Retracted
- Share via
From Bloomberg News
Schering-Plough Corp., the maker of Claritin allergy pills, retracted its estimate for profit this year and said first-quarter earnings tumbled 71% as competition from generic drugs hurt sales.
Net income fell to $173 million, or 12 cents a share, from $600 million, or 41 cents, in the first quarter of last year. Sales decreased 19% to $2.07 billion, the company said.
Shares of Kenilworth, N.J.-based Schering rose 41 cents to $18.71 on the New York Stock Exchange.
From Bloomberg News
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
